Boston Scientific is set to acquire Penumbra for $14.5 billion, marking a significant expansion into the high-growth thrombectomy and neurovascular device markets. This major consolidation could catalyze further M&A activity, creating investment opportunities among other innovative companies in the cardiovascular sector.
Published on January 17
Boston Scientific's massive £14.5 billion Penumbra deal has set the stage for a wave of acquisitions in cardiovascular technology. Smaller innovative firms could become prime targets for major corporations seeking growth.
The global rise in cardiovascular diseases is driving unprecedented demand for innovative medical devices. Companies with proven technologies and patents are increasingly valuable in this expanding market.
These carefully selected companies operate in high-growth niches like thrombectomy and neuromodulation. Their specialised expertise makes them attractive acquisition candidates for industry giants looking to expand their portfolios.
Boston Scientific's £14.5 billion acquisition of Penumbra signals a major consolidation wave in the cardiovascular technology sector. Large corporations are aggressively pursuing smaller, innovative firms with specialised patents and proven devices to expand their portfolios in high-growth areas like thrombectomy and neurovascular intervention.
This group focuses on companies developing cutting-edge cardiovascular devices and technologies. The rising global prevalence of cardiovascular diseases is driving demand for innovative solutions, making these specialised firms attractive acquisition targets for larger medical technology corporations seeking growth and market share.
These companies were handpicked by professional analysts as potential beneficiaries of the ongoing M&A activity in the cardiovascular sector. Each represents a strategic position in specialized markets like neuromodulation, vascular devices, and interventional cardiology that could attract acquisition interest from major industry players.
This basket's total market capitalisation is $195.73B and is heavily anchored by a few large-cap stocks. The concentration in top weights generally reduces volatility and gives the basket a more stable profile.
PEN: $13.76B
MDT: $124.05B
EW: $48.95B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+97.98%
On average, analysts expect assets in this group to grow 97.98% over the next year.
12 of 15 assets in this group are rated Buy by professional analysts.
